|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03320 CHINARES PHARMA
Nominal 
5.240 -0.090 (-1.689%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 128,597,588 | 4.705% | 244,703,884 | 218,182,994 | 193,611,454 | 168,677,851 |
| Cost of Sales | (107,664,092) | 4.470% | (206,366,398) | (184,563,943) | (164,684,722) | (141,499,042) |
| Gross Profit | 20,933,496 | 5.935% | 38,337,486 | 33,619,051 | 28,926,732 | 27,178,809 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 198,770 | -6.246% | 417,106 | 332,341 | 256,395 | 174,089 | |
| Profit / (Loss) before Taxation | 7,046,076 | 12.141% | 9,880,227 | 8,361,081 | 6,874,689 | 5,954,812 | |
| Taxation | (1,505,520) | 20.049% | (2,105,224) | (1,703,152) | (1,439,805) | (1,474,387) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (2,935,750) | 25.060% | (3,920,756) | (3,157,659) | (2,353,460) | (1,705,534) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,604,806 | -2.866% | 3,854,247 | 3,500,270 | 3,081,423 | 2,774,891 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 805,838 | -32.640% | 1,798,626 | 1,732,289 | 1,647,741 | 2,085,093 |
| Depreciation & Amortisation | 1,628,020 | 6.440% | 3,164,365 | 2,558,441 | 2,307,162 | 2,056,937 |
| Directors' Emoluments | -- | -- | 8,088 | 11,224 | 10,977 | 7,662 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 41.000 | -4.651% | 61.000 | 56.000 | 49.056 | 43.764 |
| DPS (cts) | 8.300 | -- | 15.400 | 14.292 | 12.264 | 10.099 |
| Dividend Payout Ratio (%) | 20.244% | -- | 25.246% | 25.522% | 25.000% | 23.077% |
| Cash flow per share ($) | -- | -- | 2.475 | 1.722 | 1.671 | 1.099 |
| NBV per share ($) | 7.699 | -- | 7.315 | 6.933 | 6.635 | 6.225 |
| Remarks: | Real time quote last updated: 28/11/2024 10:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,604,806 |
| %Change | -2.866% |
| EPS / (LPS) | RMB 0.410 |
| NBV Per Share (¥) | RMB 7.699 |